QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:ORPN

Bioblast Pharma (ORPN) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)
Free ORPN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.39
▼
$1.52
50-Day Range
$11.50
▼
$28.49
52-Week Range
$6.16
▼
$30.00
Volume
92,429 shs
Average Volume
N/A
Market Capitalization
$588,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
ORPN stock logo

About Bioblast Pharma Stock (NASDAQ:ORPN)

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

ORPN Stock News Headlines

April 10, 2024 | markets.businessinsider.com
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
March 14, 2024 | barrons.com
AnaptysBio Inc.
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
February 23, 2024 | msn.com
What's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?
February 23, 2024 | morningstar.com
Lantern Pharma Inc Ordinary Shares LTRN
February 18, 2024 | msn.com
QBiotics wins FDA orphan status for rainforest-derived cancer drug
February 18, 2024 | seekingalpha.com
PBSV Pharma-Bio Serv, Inc.
February 5, 2024 | markets.businessinsider.com
AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
January 4, 2024 | markets.businessinsider.com
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
November 3, 2023 | marketwatch.com
Plus Therapeutics Shares Jump Premarket on FDA Orphan Designation
March 31, 2023 | wsj.com
Changzhou Qianhong Bio-Pharma Co. Ltd. A
March 1, 2023 | marketwatch.com
2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for Development
February 18, 2023 | marketwatch.com
Spinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028
February 15, 2023 | marketwatch.com
Spinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028
February 13, 2023 | thestreet.com
BioBlast Scant Data Links Drug to Improved Swallowing in Patients
January 30, 2023 | seekingalpha.com
BioMarin: Opportunity To Score Home Run With Latest Regulatory Advancements
January 18, 2023 | marketwatch.com
Spinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028
October 16, 2022 | finance.yahoo.com
Orphan Drugs Market Size to Hit USD 340.84 Billion by 2027
September 21, 2022 | seekingalpha.com
ENLV Enlivex Therapeutics Ltd.
August 31, 2022 | marketwatch.com
BioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans Progressiva
August 31, 2022 | msn.com
BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate
August 12, 2022 | finance.yahoo.com
Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease
August 11, 2022 | seekingalpha.com
BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript
August 1, 2022 | finance.yahoo.com
Biosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic Syndromes
July 12, 2022 | markets.businessinsider.com
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma
July 8, 2022 | apnews.com
Global Orphan Drugs Global Market Report (2022 to 2031) - Featuring Amgen, Biogen, Novartis and Novo Nordisk Among Others - ResearchAndMarkets.com
See More Headlines
Receive ORPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORPN
CUSIP
N/A
CIK
1596812
Web
bioblastpharma.com
Phone
(722) 670-8072
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.56 per share
Price / Book
0.19

Miscellaneous

Outstanding Shares
420,000
Free Float
N/A
Market Cap
$588,000.00
Optionable
Not Optionable
Beta
1.41
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Oren Hershkovitz
    Chief Executive Officer
  • Shachar Shlosberger
    Chief Financial Officer
  • Dror Mevorach
    Chief Scientific & Medical Officer
  • Odelia Ben-Shitrit
    Head-Clinical Operations

Key Competitors

View All Competitors

ORPN Stock Analysis - Frequently Asked Questions

When did Bioblast Pharma's stock split?

Shares of Bioblast Pharma reverse split on Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Bioblast Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO).

This page (NASDAQ:ORPN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The #1 Crypto for 2024
InvestorPlace
Your Money is Not Safe
American Alternative